Browse the evidence

Obesity and weight gain exacerbate insulin resistance in PCOS by selectively impairing the PI3-K pathway while leaving the MAP-K pathway intact, leading to compensatory hyperinsulinemia and hyperandrogenism.

Understanding that weight gain worsens the hormonal imbalance in PCOS through specific insulin pathway defects can help patients see why weight management is critical for symptom control, not just appearance.

A multicomponent workplace wellness program (nutrition, physical activity, stress reduction) significantly increases self-reported healthy behaviors (exercise, weight management) but has no significant effect on clinical health markers, healthcare spending, or employment outcomes after 18 months.

If you are an employer considering a wellness program, expect it to boost employee engagement and self-reported healthy habits (like exercising more), but do not expect it to lower your healthcare bills or improve clinical health metrics (like weight or blood pressure) within 18 months. The program's value lies in behavioral nudges, not immediate clinical or financial ROI.

Vitamin D supplementation (specifically Vitamin D3) does not significantly reduce all-cause mortality in adults compared to placebo, although it significantly reduces cancer mortality by 16%.

Taking Vitamin D supplements will not help you live longer, according to this large review of 75,000+ people. However, it may help reduce the risk of dying from cancer. Focus on maintaining healthy levels for bone health or other indicated reasons, but do not expect it to extend your lifespan.

Racial and ethnic minority groups in the US experience significantly worse sleep health outcomes, including shorter duration, lower efficiency, and higher prevalence of sleep disorders, compared to non-Hispanic Whites.

If you belong to a racial or ethnic minority group, you may face systemic barriers that make getting adequate sleep harder, regardless of your personal habits. Focus on controllable factors like sleep hygiene and stress management, but recognize that advocating for policy changes and community support is also part of addressing sleep health disparities.

Insulin resistance (IR) is a major driver of PCOS pathophysiology, present in 65-95% of women with PCOS, and is independent of and exacerbated by obesity.

Insulin resistance is a core feature of PCOS, affecting most women with the condition, regardless of weight. Managing insulin levels is crucial for treating PCOS symptoms and reducing long-term health risks like type 2 diabetes.

Real-time cardiac telerehabilitation reduces sedentary time and lowers medication costs compared to center-based cardiac rehabilitation, while center-based rehabilitation results in smaller waist and hip circumferences.

While both programs improve fitness, telerehabilitation helps patients sit less and costs less in medications. However, center-based programs might lead to slightly better reductions in waist and hip size. Choose telerehabilitation if cost and convenience are priorities, or center-based if anthropometric reduction is the primary goal.

Sarcopenia is defined by the presence of both low muscle mass and low muscle function (strength or physical performance).

To diagnose sarcopenia, you need both low muscle mass and low muscle function (strength or performance).

Metabolic dysfunction (Metabolic Syndrome) significantly increases CHD risk regardless of body weight, with metabolically unhealthy normal weight individuals having more than double the risk of metabolically healthy normal weight individuals.

If you are normal weight, you are not immune to heart disease. If you have high blood pressure, high triglycerides, low HDL, high blood sugar, or a large waist, your risk is more than double that of a normal weight person with healthy metabolic markers. Address these metabolic issues through lifestyle changes or medication.

Physical inactivity is a major global health risk, ranking as the fourth leading cause of mortality and contributing to 3.2 million deaths annually, primarily through cardiovascular disease, diabetes, hypertension, and certain cancers.

Recognize that physical inactivity is a critical health risk, comparable to smoking or obesity. Prioritize increasing daily movement to reduce the risk of cardiovascular disease, diabetes, and hypertension. In Arab countries, be aware that cultural and gender-specific barriers may exist, requiring tailored solutions to overcome them.

Obesity is the primary environmental factor driving insulin resistance and the pathogenesis of Type 2 Diabetes (T2D) through mechanisms involving visceral fat distribution, ectopic lipid deposition, and gut microbiome dysbiosis.

Focus on reducing visceral and ectopic fat through sustainable lifestyle changes, as this is the most effective way to improve insulin sensitivity and prevent Type 2 Diabetes. Prioritize weight management, especially in high-risk groups, as it is the primary driver of the disease.

Critical Power (CP) is the gold standard for defining the maximal metabolic steady state, whereas Maximal Lactate Steady State (MLSS) systematically underestimates this threshold due to methodological limitations.

Stop using Maximal Lactate Steady State (MLSS) or arbitrary 60-minute functional thresholds as your primary guide for endurance capacity. Instead, determine your Critical Power (CP) using a power-duration curve model. CP accurately separates the 'heavy' intensity domain (where homeostasis is possible) from the 'severe' domain (where fatigue is inevitable). Training prescriptions based on CP are more physiologically robust than those based on MLSS, which tends to underestimate your true sustainable power.

Oral semaglutide (up to 14 mg daily) significantly reduces the risk of major adverse cardiovascular events (MACE) in high-risk patients with type 2 diabetes, specifically those with established atherosclerotic cardiovascular disease or chronic kidney disease.

If you have type 2 diabetes and existing heart disease or kidney issues, taking oral semaglutide (up to 14 mg daily) alongside your standard care significantly lowers your risk of heart attack, stroke, or cardiovascular death compared to a placebo. This benefit is achieved without increasing serious side effects, making it a viable option for cardiovascular risk reduction in this high-risk group.

Dietary phytate is a potent inhibitor of zinc absorption, significantly reducing fractional zinc absorption when the phytate:zinc molar ratio exceeds 15.

If your diet is plant-based, high phytate content (found in grains and legumes) can block up to 45% of zinc absorption if the phytate:zinc ratio is high. To improve zinc status, consider soaking, fermenting, or sprouting grains/legumes to reduce phytate, or include animal products which have higher zinc bioavailability.

Activation of the melanocortin-4 receptor (MC4R) by alpha-melanocyte-stimulating hormone (alpha-MSH) decreases energy intake and increases energy expenditure.

Your brain uses a specific hormonal pathway (leptin/insulin -> POMC -> MC4R) to regulate hunger and energy use. When this system works, it helps you stop eating and burn energy. Disruptions in this pathway (due to genetics or obesity) can make this harder, but the mechanism itself is a valid target for understanding appetite control.

GLP-1 receptor agonists (GLP-1RAs) reduce major adverse cardiovascular events (MACE), cardiovascular mortality, and all-cause mortality in patients with type 2 diabetes, particularly those with established cardiovascular disease.

If you have Type 2 Diabetes and existing heart disease or high risk, GLP-1 receptor agonists (like liraglutide or semaglutide) are proven to significantly lower your risk of heart attack, stroke, and death. This benefit exists alongside blood sugar control. However, if you have heart failure with reduced ejection fraction, these drugs may increase risks, so discuss your specific heart condition with your doctor before starting.

Semaglutide has a favorable cardiovascular safety profile, with cardiovascular outcome trials (SUSTAIN-6, PIONEER-6) showing no increased risk of major adverse cardiovascular events (MACE) compared to placebo.

Semaglutide is safe for your heart. Large studies have shown it does not increase the risk of heart attack, stroke, or cardiovascular death in people with type 2 diabetes, and may even offer benefits.

Standardized exercise training produces highly variable cardiorespiratory fitness (CRF) responses in humans, with a significant portion of individuals showing no improvement (non-responders) despite adherence to prescribed protocols.

If you exercise consistently but see no change in your fitness tests, you are likely a 'non-responder' to that specific dose. This is common and often genetic. Do not stop exercising, as other health benefits likely persist. Consider adjusting the type, intensity, or duration of exercise to find a protocol that works for your biology.

The health benefits attributed to ellagitannin-rich foods (pomegranates, walnuts) are primarily driven by Urolithin A, but these benefits are conditional on the individual's gut microbiota composition (metabotype).

Eating pomegranates or walnuts is healthy, but your gut bacteria must convert them into Urolithin A for maximum benefit. If you are a 'non-producer' (UM-0), you might not get these specific benefits. Testing your metabotype or using Uro-A supplements can ensure you get the intended effects.

Tirzepatide does not increase the risk of hypoglycemia compared to placebo and has a lower risk compared to basal insulin.

Unlike insulin, Tirzepatide does not increase the risk of low blood sugar (hypoglycemia) when used alone. In fact, it has a lower risk of causing hypoglycemia compared to basal insulin. This makes it a safer option for patients who are concerned about blood sugar lows.

Reduced HRV is a consistent predictor of various diseases, including diabetes, cardiovascular disease, obesity, and psychiatric disorders, and is associated with inflammation and insulin resistance.

Monitor your HRV as a general indicator of your health status. Consistently low HRV may be a sign of underlying issues such as inflammation, insulin resistance, or stress. While not a diagnostic tool on its own, it can help identify individuals at risk for cardiovascular, metabolic, and psychiatric conditions, prompting earlier lifestyle interventions or medical consultation.

Fermentation of dietary fibers by gut bacteria produces short-chain fatty acids (SCFAs) like butyrate, acetate, and propionate, which reduce inflammation, provide energy to colon cells, and regulate metabolism.

Eat fiber-rich foods to feed your gut bacteria, which will produce beneficial short-chain fatty acids that reduce gut inflammation and support colon health.

SGLT2 inhibitors and GLP-1 receptor agonists provide cardiovascular benefits (reduced MACE and heart failure hospitalization) and slow kidney disease progression, distinct from older glucose-lowering drugs.

If you have Type 2 Diabetes and heart or kidney issues, ask your doctor about SGLT2 inhibitors (like Jardiance, Farxiga) or GLP-1 agonists (like Ozempic, Trulicity). These drugs protect your heart and kidneys beyond just lowering sugar, unlike older diabetes medications.

Bariatric surgery resolves obesity-associated gonadal dysfunction (PCOS in women, MOSH in men) in the vast majority of severely obese patients, with resolution rates of 96% for PCOS and 87% for MOSH.

If you are severely obese and have been diagnosed with PCOS or Male Obesity-Associated Secondary Hypogonadism (MOSH), bariatric surgery is the most effective treatment for resolving these conditions. Unlike diet or medication which often only manage symptoms, surgery addresses the underlying metabolic drivers, leading to resolution in nearly all women with PCOS and most men with MOSH. Consult a bariatric specialist to see if you are a candidate.

Bariatric surgery reverses the sex-specific hormonal imbalances caused by obesity: it increases testosterone in men and decreases testosterone in women, while increasing SHBG and decreasing estradiol in both.

Bariatric surgery normalizes sex hormones in a sex-specific way. Men typically see their testosterone levels rise to normal ranges, while women see their elevated testosterone levels drop. Both groups see an increase in Sex Hormone Binding Globulin (SHBG) and a decrease in Estradiol. This hormonal normalization is key to resolving fertility and sexual health issues associated with obesity.